Cerevel Therapeutics Holdings Accounts Payable

Cerevel Therapeutics Holdings (CERE) currently reports a accounts payable of $11M as of March 2024. That compares with $7.3M in the prior-year period — up 48.2% year over year. Use the charts on this page to explore Cerevel Therapeutics Holdings's accounts payable history and peer comparisons.

Cerevel Therapeutics Holdings's accounts payable increased from $7.3M to $11M — a 48.2% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cerevel Therapeutics Holdings reported $11M in accounts payable as of March 2024. That compares with $7.3M in the prior-year period — up 48.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cerevel Therapeutics Holdings, and consider following CERE for alerts when major investors trade the stock.

Cerevel Therapeutics Holdings is classified in the Healthcare sector. On accounts payable, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CERE with unrelated industries.